Sarah I. Warsetsky

Papers

Total Citations

H-Index

About

Sarah I. Warsetsky is a clinician-researcher whose work centers on hereditary cancer syndromes, with a particular focus on gynecologic malignancies and their genetic underpinnings. Her most cited study, a 2015 investigation into a novel fumarate hydratase mutation in a family with atypical uterine leiomyomas and hereditary leiomyomatosis and renal cell cancer (HLRCC), has garnered 15 citations and represents a key contribution to the field. This work helped clarify the genotype-phenotype correlations in HLRCC, a rare autosomal dominant disorder that predisposes individuals to both benign uterine fibroids and aggressive renal cancers. By identifying a previously unreported mutation, Warsetsky advanced the understanding of how FH gene alterations drive tumorigenesis, offering critical insights for genetic counseling and surveillance strategies. Her research bridges clinical oncology and molecular genetics, emphasizing the importance of recognizing atypical leiomyomas as sentinel markers for underlying hereditary risk. Though her citation count reflects a focused, early-career impact, her findings have informed diagnostic criteria for HLRCC and underscore the need for multidisciplinary care in managing patients with complex hereditary cancer syndromes. Warsetsky’s work continues to influence how clinicians approach uterine leiomyomas in the context of broader cancer predisposition.